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Consumer News
FDA Approves
Controversial Birth
Control Drug
The Food and Drug Administration
("FDA") has approved the use of a
highly effective, injectable drug that
prevents pregnancy for three months.
Although the drug, called DepoProvera, is available in ninety countries and is currently being used by nine
million women, it has been the subject
of controversy for two decades in the
United States.
The contraceptive was first developed by the Upjohn Company of
Kalamazoo, Michigan, in 1957. The
FDA refused to approve the drug in
1978 because of concerns raised by
animal studies showing an increased
risk of breast and other cancers. The
drug, which is injected into the buttocks or arm, is a synthetic hormone
that mimics one of the natural hormones controls the menstrual cycle.
With a 99.6 percent effective rate, it is
one of the most reliable contraceptives
available.
Depo-Provera has been controversial with women's groups, which fear it
will be used on low income women
coercively.
But since 1978, the World Health
Organization has conducted a nineyear, worldwide study of 11,000 women
to determine if the drug increased rates
of cancer. Overall, there was no additional breast cancer in Depo-Provera
users. For women under thirty-five,
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however, the breast cancer rate increased slightly. The study also found
slightly increased rates of breast cancer
among women younger than thirtyfive who had used the drug for four
years or less. Researchers concluded
that any link between the drug and
breast cancer was weak.
The same study also found that DepoProvera protected women against endometrial cancer of the uterus.
The animal studies originally relied
upon have also been discounted after
researchers concluded that beagles, the
animals on which the drug was tested,
were not an appropriate animal model
for studying the drug.
In approving the contraceptive this
fall, the FDA cited worldwide studies
and years of use that showed the overall
risk of cancer, including breast cancer,
"to be minimal, if any."
Many family planning and reproductive health organizations applauded
the FDA's approval.
"We're glad that the FDA has recognized mounting worldwide evidence
that Depo-Provera is extremely safe
and effective," said Dr. Andrew
Kaunitx, chairman of the Association
of Reproductive Health Professionals,
a group that promotes reproductive
health. The FDA's approval of DepoProvera this fall and the approval of
Norplant, a time released implant which
prevents pregnancy for five years, in
December 1990, has greatly increased
the choices available to American
women.
"This drug presents another longterm effective option for women to
prevent pregnancy," said Dr. David
Kessler, the commissioner of Food and
Drugs. "As an injectable, given once
every three months, Depo-Provera
eliminates problems related to missing
a daily dose."
However, some women's groups
still worry about the link to cancer.
"We are very sorry it was approved,"
said Cindy Pearson of the National
Women's Health Network. "We are

concerned about bringing a drug linked
to cancer into a country where the risk
of breast cancer already is so high."
The most common side effects are
weight gain and menstrual irregularities. Some women's menstrual cycles
discontinue altogether. Research has
also shown that the drug may contribute to osteoporosis, a disease that leaves
bones thin, brittle, and easily breakable. As one of the conditions of
approval, Upjohn agreed to continue
studying the drug's link to osteoporosis.
Many women who cannot take birth
control pills may be able to take DepoProvera because it contains no estrogen.
The FDA warned that doctors prescribing the drug should make sure the
patient is not pregnant. The drug also
should not be used by women suffering
from acute liver disease, unexplained
vaginal bleeding, breast cancer, or
blood clots in the legs, lungs, or eyes.
The company expects to price the
drug in the range of birth control pills,
which cost $15 to $25 a month. But
health groups say they hope the drug
will be priced within the reach of lowincome women.
"It will be of little use to women if
they can't afford to use it," said Dr.
Kaunitx. He said that Norplant, which
costs $500 to $800, is priced out of the
reach of low-income women. oo

GM's Gas Tanks are
Fueling Safety Debate
In what could turn out to be the
biggest controversy over automobile
gas tank design since the Ford Pinto,
consumer advocates have charged that
General Motors ("GM") full-size
pickup trucks should be recalled because they are susceptible to catching
fire in a collision due to faulty design
of the fuel tank. The National Highway Traffic Safety Administration
Loyola Consumer Law Reporter
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("Safety Administration") has opened
an investigation to determine whether
there is a design defect, and the agency
could order a recall.
Consumer groups claim that more
people have died in post-crash fires
involving GM trucks than any other
vehicle. According to the Center for
Automobile Safety, more than 300
people have been killed in fiery crashes
involving GM pickups. In comparison, twenty-seven people died in 1971
to 1976 Ford Pintos, a car whose design
was the subject of lawsuits and controversy in the 1970s.
"We believe that 1973 through 1987
full-size GM pickups are the Pintos of
the '90s," said Thomas Smith, director
of Public Citizen's office in Austin,
Texas.
GM is the defendant in more than
100 lawsuits filed in connection with
the fuel tank design. Already, the
company has settled some of the suits
with payments as large as $1 million.
The pickup trucks with the allegedly
faulty design were made from 1973 to
1987. Of the ten million built, approximately half are still on the road.
Company documents furnished to
federal safety officials and also made
public after settlement of a Texas lawsuit show that GM knew as early as
1983 that its trucks could be made
"much less vulnerable" in collisions
where the fuel tank might break open.
But the design of the trucks was not
changed until the 1988 model year, and
GM says the change was made only for
design and not safety reasons.
According to consumer advocates,
the problem with the fuel tank is that it
is located outside the vehicle's frame
rails, where only a thin piece of sheet
metal protects the tank. In a sideimpact crash, the tank can be compressed between the striking vehicle
and the frame, causing the tank to
rupture. The gasoline, under pressure,
can then spray from the tank.
"It just envelopes the vehicle," said
Clarence Ditlow, executive director of
the Center for Auto Safety, a Washington, D.C., based consumer advocacy
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organization. "With any ignition source,
you have a fireball."
Competing pickup trucks made by
Chrysler and Ford have the fuel tanks
inside the frame rail.
Ditlow's organization has called for
GM to recall the trucks. But GM so far
has refused, saying that the trucks are
safe and that they meet all federal
motor vehicle safety standards.
"These trucks are absolutely safe to
drive," said Robert Sinke Jr., GM director of engineering analysis. "This
whole situation has been blown out of
proportion."
The opening of the Safety Administration investigation is the first formal
step in an administrative proceeding to
determine the safety of the GM trucks.
The government will review 70,000
documents provided to it by the
automaker and will take the unusual
step of conducting its own crash tests.
If the investigation warrants it, the
agency could ask GM to recall the
trucks.
A GM spokesman said that the
nation's leading automaker welcomed
the opening of the Safety Administration investigation. "After a full investigation, we trust and believe the agency
will conclude - as any fair reviewer
would - that there is no basis upon
which to conclude that these vehicles
contain a safety-related defect." .

Will New Food Labels be
Clearer or Just Cluttered?
By the summer of 1994, consumers
will notice a big difference on the can
of tuna and other foods they buy at the
local supermarket: Every one of the
300,000 food labels on processed foods
will be completely redesigned, giving
shoppers more and better information
about the foods they eat.
The new food labels will be the
result of a complete overhaul of the
food labeling system announced by the
Food and Drug Administration ("FDA")
in December 1992. The change re-

quires consistent nutritional information on labels for nearly all processed
foods and defines such buzzwords as
"light," "low sodium," and "high fiber" so those phrases mean the same
thing for all foods.
Nutritionists, public health officials,
and consumers are welcoming the new
food labeling regulations as an important step in changing the typical American diet, which contains too much fat
and sodium and not enough grains,
fruits, and vegetables. Most importantly, the new labels will make it
easier for consumers to calculate the
amount of fat and sodium they are
eating in a day.
"With this new label, American consumers don't need to worry about
grams. If the label says a food contains
30 percent of their day's fat allotment,
you know that it's going to be high in
fat. If the label says it contains 3
percent, you can be sure that it's lowfat. For the first time, consumers don't
have to pull out their calculators," said
David Kessler, the FDA Commissioner.
A new food label will show fat,
cholesterol, sodium, carbohydrates, and
protein as a percentage of what is considered a healthy daily intake. In addition, the FDA reviewed more than
47,000 suggestions submitted by industry and consumers to determine
exactly what kind of health and nutritional claim a food manufacturer can
make. For example, the rules say that a
food can be described as "light" or "lite"
on the label only if it has 50 percent less
fat than the food to which it is compared.
But some industry trade groups criticized the new labels, saying they will
be cluttered and hard to understand.
"The side panel is going to be extremely dense with information," said
Regina Hildwine, director of regulatory affairs for the National Food Processors Association. "A can of tuna
fish has fourteen square inches on its
label. It's going to take the better part
of those fourteen square inches just to
present this nutrition information,
which doesn't leave an awful lot of
room to identify the product." o+°

